Steven Axon

Steven Axon is the Chief Executive Officer at Prothelia. Prior to Prothelia, Steve served as Chief Business Officer of Apellis Pharmaceuticals helping to build the company from a small 15 person team to a successful IPO and expanded presence in Boston. Prior to joining Apellis, Mr. Axon worked at Merck Serono in Switzerland and the US with progressive leadership roles in Corporate Strategy, Alliance Management and Business Development. Most recently, he served as Senior Vice President, Business Development. During his tenure at Merck Serono, Mr. Axon led more than 50 transactions across all therapeutic areas and stages of development. Prior to joining Merck Serono, Mr. Axon was Director of Strategy and Business Development at Serono from 2005 until its acquisition by Merck KGaA in 2007. During the transition, Mr. Axon served as the Serono business lead for the Merck Serono integration. Mr Axon received a B.Sc and M.Sc. in biomechanical and biomedical engineering from the University of Toronto and his M.B.A. from the International Institute for Management Development in Lausanne, Switzerland.